Ascendis Pharma ADR ASND

$243.37 +0.38 (0.16%)

Valuation

Market cap
14,901,862,000
Revenue TTM
$814,760,000
Net income TTM
$-258,000,000
PE ratio
130.18
Forward PE
66.09
Profit margin
-31.67%
Debt to equity
0.31

Trading

Volume
575,400
Avg volume
749,716
Day's range
$240.79 – $244.58
Shares out
62,377,000
Stochastic %K
96%
Beta
0.38
Analysts
Strong Sell
Price target
$311.14

Price

Company profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipe...

Show more

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

Industry
Biotechnology
Sector
Healthcare
Phone
45 70 22 22 44
Website
https://ascendispharma.com
Address
Tuborg Boulevard 12, Hellerup, Denmark

Latest news

Stocktwits

mikesterz7 Oct 18, 2:15 PM
$ASND Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.
0 replies
severeblast Oct 16, 8:54 PM
$ASND bad news and barley dropped...
0 replies
StocktwitsNews Oct 16, 8:30 PM
ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug $ASND $TCAF $IBB https://stocktwits.com/news/equity/markets/asnd-shares-shrug-off-positive-european-opinion-for-fda-approved-achondroplasia-drug/cZxKWRBRBtT
0 replies
filecrux Oct 16, 12:44 PM
$ASND Copenhagen biopharma Ascendis Pharma plans to launch its weekly achondroplasia drug TransCon CNP (YUVIWEL) in Germany in Q1 2027 if the EU approves it, after the EMA's CHMP backed approval for children 2 and older. The drug has been FDA-approved since Feb 2026; Ascendis was valued at about $14.05B at $226.62 at 16:00 ET Oct 15, 2026. The other side: EMA will now review whether it keeps its orphan designation, and a CHMP opinion is not approval. The European Commission's final decision is expected in Q4 2026.
0 replies
mktrdr59 Oct 10, 7:37 PM
$ASND three wave corrective-looking pullback from the July high may be complete at the Fib .786 retracement level, with bullish divergences on the technical indicators
0 replies
SmartFlowTrading Oct 9, 2:26 PM
5 Bullish Stocks on My Watchlist Based on Options Flow I'm seeing some selective bullish positioning despite the broader market weakness. These five names stand out from the latest institutional options activity: $AVGO — $2.16M in call buying near current prices, with consistently bullish flow over the past week. One of the cleaner setups. $PANW — $3.09M in November calls, supported by repeated bullish activity. Cybersecurity continues to attract interest. $SYK — $1.39M in November calls ahead of October 29 earnings. Worth monitoring for follow-through. $ASND — $430K in calls just 3% above spot. Smaller premium, but the positioning is interesting. $PHM — $167K in November calls, supported by bullish activity in the broader homebuilding sector. Earnings on October 22.
0 replies
SenefAS Oct 5, 7:49 PM
I hope you are on the train of Genmab 😉 … $GMAB $ABBV Next one on the radar it’s Ascendis $ASND
0 replies
Quantumup Oct 2, 12:50 PM
Guggenheim⬆️ $MBX's PT to $150 & reit'd Buy. ~Believes MBX 4291, should the Part C data show a once-monthly profile that is competitive with tirz—canvuparatide could make MBX a $8B+ Co.—rest of the obesity portfolio remain pot'l upside. $LLY VKTX NVO GPCR KLRA $ASND RHHBY Here's what Guggenheim said in its note to investors: https://x.com/Quantumup1/status/2106003575075676364?s=20
0 replies